DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation

Launched by UNIVERSITAIR ZIEKENHUIS BRUSSEL · Oct 29, 2020

Keywords

ClinConnect Summary

The DEPO-Trigger Trial is studying a new approach to help protect the ovaries of women with early-stage breast cancer who need chemotherapy. This trial is looking at a method that combines two treatments: one that helps mature eggs in the ovaries and another that temporarily suppresses ovarian function to prevent complications. The main goal is to see if this combined treatment is safe and effective for women who want to preserve their fertility by freezing their eggs or embryos before starting cancer treatment.

To participate in this trial, women must be under 36 years old, have a healthy weight, and have early-stage breast cancer. They should also have the approval of their oncologist and be willing to sign a consent form. As a participant, you can expect to undergo a series of tests to monitor your hormone levels and the health of your ovaries during the study. This trial is currently recruiting participants and aims to provide important information about this new fertility preservation strategy for young women facing breast cancer treatment.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Age \<36y
• • BMI ≥ 18 and ≤ 35 kg/m²
• • Early stage breast cancer
• • Any hormone receptor status
• • Any HER status
• • Cryopreservation of oocytes and/or embryos
• • Oncologist's approval to participate to the DEPO-trigger trial
• • Signed informed consent form
• Exclusion Criteria:
• • Contra-indications for controlled ovarian stimulation or oocyte retrieval
• • Necessity of neo-adjuvant chemotherapy